tradingkey.logo

Janux Therapeutics, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor Therapy

ReutersJan 22, 2026 12:11 PM

- Janux Therapeutics Inc JANX.O:

  • JANUX THERAPEUTICS ANNOUNCES COLLABORATION AND EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH BRISTOL MYERS SQUIBB TO DEVELOP A NOVEL TUMOR-ACTIVATED THERAPEUTIC FOR SOLID TUMORS

  • JANUX THERAPEUTICS INC - TO RECEIVE UP TO $50 MILLION UPFRONT, $800 MILLION IN MILESTONES

  • JANUX THERAPEUTICS: UNDER TERMS, CO IS ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY & COMMERCIAL MILESTONES UP TO ABOUT $800 MILLION IN AGGREGATE

  • JANUX THERAPEUTICS INC - AS PART OF COLLABORATION, CO WILL COMPLETE PRECLINICAL DEVELOPMENT UP TO IND SUBMISSION

  • JANUX THERAPEUTICS INC - AS PART OF COLLABORATION, BRISTOL WILL HOLD IND & BE RESPONSIBLE FOR SUBSEQUENT DEVELOPMENT & GLOBAL COMMERCIALIZATION

  • JANUX THERAPEUTICS INC - CO ALSO ENTITLED TO TIERED ROYALTIES ON GLOBAL SALES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI